APLS

26.18

0.34% -0.09

Dopo l'orario di chiusura: 28.18 2.00 +7.64%

Apellis Pharmaceuticals Inc (APLS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché APLS Giù? Forum Previsione

Precedente Chiudi:

$26.27

Aprire:

$26.45

Volume 24 ore:

7.62M

Relative Volume:

3.04

Capitalizzazione di mercato:

$3.26B

Reddito:

$715.22M

Utile/perdita netta:

$-250.10M

Rapporto P/E:

-4.9867

EPS:

-5.25

Flusso di cassa netto:

$-205.58M

1 W Prestazione:

-11.49%

1M Prestazione:

-6.50%

6M Prestazione:

-36.63%

1 anno Prestazione:

-46.68%

Intervallo 1D:

$25.76

$26.66

Intervallo di 1 settimana:

$25.76

$29.94

Portata 52W:

$24.34

$73.80

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Nome

Apellis Pharmaceuticals Inc

Settore

Healthcare (1196)

Industria

Biotechnology (683)

Telefono

617-977-5700

Indirizzo

100 FIFTH AVENUE, WALTHAM, KY

Dipendente

702

Cinguettio

@ApellisPharma

Prossima data di guadagno

2024-12-05

Ultimi documenti SEC

APLS's Discussions on Twitter

Confronta APLS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
APLS	26.18	3.26B	715.22M	-250.10M	-205.58M	-5.25
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-05	Aggiornamento	Jefferies	Hold → Buy
2023-12-14	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-11-09	Iniziato	Goldman	Buy
2023-11-02	Iniziato	Mizuho	Neutral
2023-10-06	Aggiornamento	JP Morgan	Neutral → Overweight
2023-09-15	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-08-29	Reiterato	Citigroup	Buy
2023-08-03	Downgrade	JP Morgan	Overweight → Neutral
2023-08-01	Downgrade	BofA Securities	Buy → Neutral
2023-01-03	Downgrade	Wells Fargo	Overweight → Equal Weight
2022-11-10	Downgrade	Jefferies	Buy → Hold
2022-07-19	Iniziato	H.C. Wainwright	Buy
2022-06-17	Ripresa	Stifel	Buy
2022-04-14	Downgrade	ROTH Capital	Neutral → Sell
2021-12-08	Iniziato	Wells Fargo	Overweight
2021-11-29	Downgrade	ROTH Capital	Buy → Neutral
2021-09-10	Reiterato	BMO Capital Markets	Outperform
2021-09-10	Reiterato	Credit Suisse	Neutral
2021-09-10	Reiterato	Needham	Buy
2021-09-10	Reiterato	Oppenheimer	Outperform
2021-09-10	Downgrade	Wedbush	Outperform → Neutral
2021-08-19	Iniziato	Jefferies	Buy
2021-08-19	Aggiornamento	Wedbush	Neutral → Outperform
2021-05-21	Iniziato	UBS	Buy
2021-04-16	Iniziato	Goldman	Buy
2020-11-19	Iniziato	Needham	Buy
2020-09-01	Iniziato	Stifel	Buy
2020-07-20	Iniziato	ROTH Capital	Buy
2020-06-17	Iniziato	BTIG Research	Neutral
2020-04-01	Iniziato	Raymond James	Strong Buy
2020-03-31	Iniziato	BMO Capital Markets	Outperform
2020-03-11	Aggiornamento	Wedbush	Underperform → Neutral
2020-01-07	Iniziato	SVB Leerink	Mkt Perform
2019-12-19	Iniziato	BofA/Merrill	Buy
2019-11-22	Iniziato	Wedbush	Underperform
2019-11-05	Iniziato	Credit Suisse	Neutral
2019-08-01	Reiterato	Cantor Fitzgerald	Overweight
2019-07-12	Aggiornamento	JP Morgan	Neutral → Overweight
2019-03-29	Iniziato	Robert W. Baird	Outperform
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-07-30	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-05-24	Iniziato	Cantor Fitzgerald	Overweight
2018-04-12	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-02-08	Iniziato	B. Riley FBR, Inc.	Buy

Mostra tutto

Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie

Nov 17, 2024

GSA Capital Partners LLP Purchases Shares of 28,584 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Nov 17, 2024

Nov 14, 2024

T. Rowe Price Investment Management Reduces Stake in Apellis Pha - GuruFocus.com

Nov 14, 2024

Nov 12, 2024

Apellis Pharmaceuticals to Present at Jefferies London Healthcare Conference 2024 | APLS Stock News - StockTitan

Nov 12, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference - The Manila Times

Nov 12, 2024

Nov 10, 2024

(APLS) Trading Signals - Stock Traders Daily

Nov 10, 2024

Nov 09, 2024

Fiera Capital Corp Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Nov 09, 2024

Nov 08, 2024

Wellington Management Group LLP Reduces Stake in Apellis Pharmac - GuruFocus.com

Nov 08, 2024

HC Wainwright Has Negative Outlook of APLS FY2024 Earnings - MarketBeat

Nov 08, 2024

William Blair Issues Pessimistic Forecast for APLS Earnings - MarketBeat

Nov 08, 2024

Nov 07, 2024

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript - MSN

Nov 07, 2024

Robert W. Baird Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat

Nov 07, 2024

Wedbush Cuts Earnings Estimates for Apellis Pharmaceuticals - MarketBeat

Nov 07, 2024

Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise By Investing.com - Investing.com Nigeria

Nov 07, 2024

Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise - Investing.com

Nov 07, 2024

Nov 06, 2024

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y - Barchart

Nov 06, 2024

Wells Fargo & Company Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $30.00 - MarketBeat

Nov 06, 2024

Old West Investment Management LLC Purchases Shares of 102,403 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Nov 06, 2024

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $32.00 by Analysts at Piper Sandler - MarketBeat

Nov 06, 2024

Needham & Company LLC Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $60.00 - MarketBeat

Nov 06, 2024

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $57.00 by Analysts at HC Wainwright - MarketBeat

Nov 06, 2024

Bank of America Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $47.00 - MarketBeat

Nov 06, 2024